|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
Hepatitis is a worldwide epidemic, and a lot of companies are working on better treatments.
This is the most helpful link I've found for an overview for the U.S. (in case it expires, I've taken the liberty of excerpting a bit):
>>Chronic Viral Hepatitis in the United States
Norah Terrault, MD, MPH
University of California
San Francisco, California
- Chronic liver disease, including cirrhosis, represents the 10th most common cause of death in the U.S. Viral hepatitis is the commonest cause of chronic liver disease with an estimated 1.25 million, 2.7 million and 70,000 individuals with chronic hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) infection, respectively.
- In the U.S., the prevalence of markers of past or chronic HBV infection is low until age 12, increasing thereafter, and is similar among males and females. The factors associated with chronic HBV infection are ethnicity (highest in non-Hispanic blacks), number of sexual partners, marital status, foreign birth, level of education, and illicit drug use.
- In the U.S., chronic HCV infection is more common in males than females and the peak prevalence is in those aged 30-39 years. HCV alone or in combination with alcohol accounts for about (60% of newly diagnosed cases of chronic liver disease.
- The prevalence of HDV in the U.S. is low. The groups with the highest prevalence of infection are injection drug users and multiply-transfused individuals (e.g. hemophiliacs).
- The risk factors for acquisition of HBV, HCV and HDV are well-established. Understanding the modes of transmission is critical in designing prevention strategies to reduce the burden of chronic liver disease.
- The geographical distribution of viral genotypes of HBV, HCV and HDV are known. Correlations between specific viral genotypes and clinical outcomes, such as disease severity and response to anti-viral treatments, are under study.<<
For the international scene check
Some other helpful links:
Monty's Page of HCV Drugs in Development
American Association for the Study of Liver Disease (you'll have to subscribe for much useful stuff, but there are a few freebies)
Hepatitis Information Network (HepNet):
CDC's Hepatitis Page:
University of Washington's Hepatitis Web Study Pages (starting at Hep C, with links to others:
This is my contribution so far to the idea of launching threads specific to indications and their markets and companies. You're welcome. Have at it!
|© 2020 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|